ArticleWorld journal of surgical oncology2025
Lesional volume in the prediction of clinically significant prostate cancer.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile MRI has significantly advanced risk stratification in prostate cancer, PIRADS scoring alone is still insufficient to solely determine which patients do not require biopsy. Beyond PIRADS scoring, data regarding lesional volume and number can easily be extracted. This study aims to investigate whether the novel parameter 'Lesional PSAD' is a better predictive biomarker for clinically significant prostate cancer than conventional PSAD.
methodsA retrospective analysis of 433 patients who underwent MRI Prostate followed by MRI-US fusion trans-perineal targeted and systematic biopsy was performed. Prostate and lesional volumes were calculated using the planimetry technique using MRI files. All PIRADS 3-5 lesions were considered significant. Lesional PSAD was calculated as: [Formula: see text] Statistical analysis with Mann-Whitney U and receiver operating curves was performed for prediction of clinically significant prostate cancer.
resultsMedian PSA at biopsy was 8.5 (6.1-11.64, ng/ml), with a prostate volume of 38.2 (29.2 -54.19, cc), and total lesional volume of 1.49cm
conclusionIntegrating lesional volume with conventional PSAD marginally increases predictive accuracy for csPCa, more so in early-onset prostate cancer, potentially aiding in decision-making for biopsy in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.